Ted W Love Global Blood Therapeutics, Inc. (GBT) insider trading activity

GBT Quotes by TradingView

Ted W Love is President and CEO of Global Blood Therapeutics, Inc.. Currently has a direct ownership of 0 shares of GBT, which is worth approximately $0. The most recent transaction as insider was on Oct 05, 2022, when has been sold 576,318 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

TED W LOVE Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 05 2022
SELL
Sale (or disposition) back to the issuer
-
576,318 Reduced 100.0%
0 Common Stock
Sep 27 2022
BUY
Exercise of conversion of derivative security
$299,972 $16.4 p/Share
18,291 Added 3.08%
576,318 Common Stock
Sep 13 2022
SELL
Bona fide gift
-
35,300 Reduced 5.95%
558,027 Common Stock
Sep 09 2022
SELL
Bona fide gift
-
221,200 Reduced 27.16%
593,327 Common Stock
Sep 01 2022
SELL
Payment of exercise price or tax liability
$626,980 $68.15 p/Share
9,200 Reduced 1.12%
814,527 Common Stock
Sep 01 2022
BUY
Exercise of conversion of derivative security
-
18,553 Added 2.2%
823,727 Common Stock
Aug 01 2022
SELL
Payment of exercise price or tax liability
$324,583 $32.4 p/Share
10,018 Reduced 1.23%
805,174 Common Stock
Aug 01 2022
BUY
Exercise of conversion of derivative security
-
20,205 Added 2.42%
815,192 Common Stock
Mar 01 2022
SELL
Payment of exercise price or tax liability
$121,690 $29.87 p/Share
4,074 Reduced 0.51%
794,987 Common Stock
Mar 01 2022
BUY
Exercise of conversion of derivative security
-
9,445 Added 1.17%
799,061 Common Stock
Feb 28 2022
BUY
Grant, award, or other acquisition
$21,285 $25.37 p/Share
839 Added 0.11%
789,616 Common Stock
Feb 01 2022
SELL
Payment of exercise price or tax liability
$308,874 $29.33 p/Share
10,531 Reduced 1.32%
788,777 Common Stock
Feb 01 2022
BUY
Exercise of conversion of derivative security
-
29,955 Added 3.61%
799,308 Common Stock
Sep 01 2021
SELL
Payment of exercise price or tax liability
$139,788 $29.85 p/Share
4,683 Reduced 0.59%
794,174 Common Stock
Sep 01 2021
BUY
Exercise of conversion of derivative security
-
9,444 Added 1.17%
798,857 Common Stock
Aug 01 2021
SELL
Payment of exercise price or tax liability
$405,932 $27.33 p/Share
14,853 Reduced 1.85%
789,413 Common Stock
Aug 01 2021
BUY
Exercise of conversion of derivative security
-
29,955 Added 3.59%
804,266 Common Stock
Feb 28 2021
BUY
Grant, award, or other acquisition
$13,398 $36.21 p/Share
370 Added 0.05%
774,311 Common Stock
Feb 01 2021
SELL
Payment of exercise price or tax liability
$885,525 $49.49 p/Share
17,893 Reduced 2.26%
773,941 Common Stock
Feb 01 2021
BUY
Exercise of conversion of derivative security
-
42,018 Added 5.04%
791,834 Common Stock

Also insider at

HGEN
HUMANIGEN, INC Healthcare
Director
SGEN
Seagen Inc. Healthcare
RPRX
Royalty Pharma plc Healthcare
Director
GPCR
Structure Therapeutics Inc.
GILD
GILEAD SCIENCES, INC. Healthcare
Director
TWL

Ted W Love

President and CEO
South San Francisco, CA

Track Institutional and Insider Activities on GBT

Follow Global Blood Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GBT shares.

Notify only if

Insider Trading

Get notified when an Global Blood Therapeutics, Inc. insider buys or sells GBT shares.

Notify only if

News

Receive news related to Global Blood Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on GBT